Hepatology

In a recent interview, Kris Kowdley, MD, discusses current data surrounding use of GLP-1 receptor agonists in NAFLD and NASH as well as the prospective role of combination agents.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

The genetic rare disease is characterized by a greater risk of premature mortality and worsened quality of life. Emerging IBAT inhibitors are helping address both issues.

The 2030 goal for global elimination of HCV looks out of reach so as key patient population including those who inject drugs are out of clinician's reach, one expert explains.

Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.

The investigators also found impaired biosynthesis of short-chain fatty acids in the coprofiltrate after analyzing the intestinal microbiome of patients with NAFLD who had SARS-CoV-2, manifested by an increase in the median acetic and propionic acids, as well as a decrease in the median butyric acid.

Counties with high liver transplantation registration rates and high liver-related mortality rates had comparable data on social vulnerability index, while travel distance was relatively shorter.

All countries in Africa now provide a three-dose infant hepatitis B vaccination beginning at age 6-8 weeks.

There is some concern that the prevalence of diseases like NASH and NAFLD may increase in the coming years.